A Phase 2 interventional study of BMS-663068 and Ritonavir in HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-03.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 128th largest by enrollment of the 210 interventional ones that give a count, is one of 9 that started in 2009, is one of 48 in phase 2, and was the 132nd registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in Romania, South Africa, Uganda
ViiV Healthcare · Sites in Netherlands
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
By country, each count listing its studies:
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
266 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 85 · Phase 2 53 · Phase 3 68 · Phase 4 18
First in 1994; this study’s year is marked. 9 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 82 across the 210 interventional studies, 328 across the 14 observational. Of the 230 that completed or were terminated, 95 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
6 of the studies in HIV Infections by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07053384ViiV HealthcareA Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV | 2027-01-22 |
| NCT07934719ViiV HealthcareMass Balance and Absolute Bioavailability of [14C]-VH4011499 | 2027-02-18 |
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
| NCT07939594ViiV HealthcareAn Evaluation of the Potential for VH4011499 Drug-drug-interactions | 2027-03-12 |
| NCT07525544ViiV HealthcareA Study to Investigate the Safety and PK of VH4770359 in Healthy Participants | 2027-05-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 266 studies in HIV Infections by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Research Hypothesis: Administration of BMS-663068, a prodrug for HIV attachment inhibitor BMS-626529, will result in a mean decrease of at least 1 log10 in HIV RNA at Day 9 following 8 days of therapy in at least one dosing regimen that is safe and well tolerated in Clade B HIV-1 infected subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clade B -1 infected subjects meeting following criteria at screening:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants received BMS-663068 600 milligram (mg) and Ritonavir (RTV) 100 mg every 12 hours (Q12H) from Day 1 to Day 8.
Drug: BMS-663068 · Drug: Ritonavir
All participants received BMS-663068 1200 mg and RTV 100 mg every night (quaque hora somni \[QHS\]) from Day 1 to Day 8.
Drug: BMS-663068 · Drug: Ritonavir
All participants received BMS-663068 1200 mg and RTV 100 mg Q12H from Day 1 to Day 8.
Drug: BMS-663068 · Drug: Ritonavir
All participants received BMS-663068 1200 mg Q12H and RTV 100 mg every 24 hours in the morning (quaque ante meridiem \[QAM\]) from Day 1 to Day 8.
Drug: BMS-663068 · Drug: Ritonavir
All participants received BMS-663068 1200 mg Q12H from Day 1 to Day 8.
Drug: BMS-663068
BMS-663068 will be administered as a tablet formulation
Ritonavir will be administered as a capsule.
Mean Logarithm With Base 10 (Log10) Change From Baseline in Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) at Day 9
The primary assessment of the antiviral activity of BMS-663068 was assessed on the log10 change from Baseline in HIV RNA to Day 9. Baseline was the last non-missing observation before first dose (Day 1 pre-dose) and change from Baseline was calculated by subtracting Baseline value from post-Baseline visit value. An analysis of covariance (ANCOVA) model correcting for Baseline HIV viral load and treatment group was used to test the differences in mean log10 decrease in HIV RNA at Day 9 between 2 regimen groups by antiretroviral treatment history (ARV \[antiretroviral\] naive, ARV experienced, and combined \[ARV naive + ARV experienced\]). For the combined group (ARV naive +ARV experienced) an additional ANCOVA was used correcting also for treatment history as an additional covariate. Only Clade B participants were included in the population.
Time frame: Baseline and Day 9
Change From Baseline in Cluster of Differentiation 4 Positive (CD4+) Cell Count and Cluster of Differentiation 8 Positive (CD8+) Cell Count
Blood samples were collected for evaluation of CD4+ and CD8+ cells at Baseline (Day 1, pre-dose), Day 8, Day 15 (Follow up) and Day 50 (study discharge). Baseline was the last non-missing observation before first dose (Day 1 pre-dose) and change from Baseline was calculated by subtracting Baseline value from post-Baseline visit value.
Time frame: Baseline (Day 1 pre-dose), Day 8, Day 15 and Day 50
Change From Baseline in Percent CD4+ Cell Count and Percent CD8+ Cell Count
Blood samples were collected for evaluation of percent CD4+ and percent CD8+ cells at Baseline (Day 1, pre-dose), Day 8, Day 15 (Follow up) and Day 50 (study discharge). Baseline was the last non-missing observation before first dose (Day 1 pre-dose) and change from Baseline was calculated by subtracting Baseline visit value from post-Baseline visit value.
Time frame: Baseline (Day 1 pre-dose), Day 8, Day 15 and Day 50
Number of Participants With Treatment Emergent Non-serious Adverse Event (Non-SAE) and Serious AE (SAE)
An AE is any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Any untoward medical occurrence resulting in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent serious outcomes were categorized as SAE. Treatment emergent adverse events (occurred after start of treatment) have been presented.Safety Population comprised of all randomized participants who used the trial medication at least once.
Time frame: Up to 50 days
Number of Participants With Any Abnormality in Physical Examination
A complete physical examination included, at a minimum, assessment of the Cardiovascular, Respiratory, Gastrointestinal and Neurological systems. A brief physical examination included, at a minimum assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). Any abnormality found by investigator during physical examination were recorded. Number of participants with any abnormality in physical examination during study have been reported.
Time frame: Up to 50 days
Number of Participants With Worst-case Abnormalities in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
Vital signs including DBP and SBP were recorded. Normal ranges were as following: For DBP, lower limit: value \<55 millimeter of mercury (mmHg) and change \<-20 mmHg; upper limit: value \>90 mmHg and change \>20 mmHg). For SBP, lower limit: value \<90 mmHg and change \<-10 mmHg; upper limit: value \>140 mmHg and change \>10 mmHg. Number of participants with worst-case abnormalities are presented. Worst-case abnormality was defined as: (1) Below Normal: at least one post-Baseline assessment was below normal range, and no post-Baseline assessment was above normal range. (2) Above Normal: at least one post-Baseline assessment was above normal range, and no post-Baseline assessment was below normal range. (3) Within Normal: all post-Baseline assessments were within normal range. It was to be considered as 'Missing' when there were no post-Baseline assessments.
Time frame: Up to 50 days
Number of Participants With Worst-case Abnormalities in Body Temperature, Respiratory Rate [RR], and Heart Rate [HR]
Vital signs (body temperature, RR, and HR) were recorded. Normal range were: For HR, lower limit: 55 beats per minute (bpm) and change \<-15 bpm; upper limit: \>100 bpm and change \>30 bpm). For temperature, lower limit: 36.0 Celsius; upper limit: \>37.5 Celsius or change \>1.7 Celsius). For RR, lower limit: 8 breaths per minute; upper limit: \>16 breaths per minute or change \>10 breaths per minute. Number of participants with worst-case abnormalities are presented. Worst-case abnormality was defined as: (1) Below Normal: at least one post-Baseline assessment was below normal range, and no post-Baseline assessment was above normal range. (2) Above Normal: at least one post-Baseline assessment was above normal range, and no post-Baseline assessment was below normal range. (3) Within Normal: all post-Baseline assessments were within normal range. It was to be considered as 'Missing' when there were no post-Baseline assessments.
Time frame: Up to 50 days
Number of Participants With Worst-case Abnormalities in Electrocardiogram (ECG) Parameters
A 12-lead ECG was recorded during the study using an ECG machine that automatically measures ECG parameters. Normal range for ECG parameters were: PR interval (upper: 200 milliseconds \[ms\]); QRS (lower: 50 ms; upper: 120 ms); Corrected QT interval by Bazett formula (QTcB) (change from Baseline - increases by \> 30 ms); Corrected QT interval by Fredericia formula (QTcF) (change from Baseline - increases by \> 30 ms). Number of participants with worst-case abnormalities are presented which was defined as: (1) Below Normal: at least one post-Baseline assessment was below normal range, and no post-Baseline assessment was above normal range. (2) Above Normal: at least one post-Baseline assessment was above normal range, and no post-Baseline assessment was below normal range. Within Normal: all post-Baseline assessments were within normal range. It was to be considered as 'Missing' when there were no post-Baseline assessments.
Time frame: Up to 50 days
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
Laboratory parameters included hematology, clinical chemistry and urine parameters. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Any abnormal laboratory test results which were considered clinically significant by the investigator were recorded on the case report form. Number of participants with any clinically significant abnormalities in laboratory parameters have been presented.
Time frame: Up to 50 days
Maximum Observed Plasma Concentration (Cmax) of BMS-626529 Following Q12H Dosing
Blood samples were collected at indicated time points to assess Cmax of BMS-626529 following Q12H dosing. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 morning dose (Anti Meridiem \[AM\]), Day 8 evening dose (Post Meridiem \[PM\]) and Day 8 morning + evening dose (AM+PM). Pharmacokinetic parameter values were derived by non-compartmental methods. Pharmacokinetic (PK) Population was used which comprised of all participants who receive BMS-663068 and provided pharmacokinetic samples.
Time frame: Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours
Cmax of BMS-626529 Following QHS Dosing
Blood samples were collected at indicated time points to assess Cmax of BMS-626529 following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 evening dose (PM) and Day 8 morning (AM) + evening dose (PM).
Time frame: Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours
Trough Observed Plasma Concentration (Ctrough) of BMS-626529 Following Q12H Dosing
Blood samples were collected at indicated time points to access Ctrough of BMS-626529 following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Days 5, 6, 7, 8, Day 8 morning dose (AM) and Day 8 evening dose (PM).
Time frame: Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours; Days 5,6,7: pre-morning dose
Ctrough of BMS-626529 Following QHS Dosing
Blood samples were collected at indicated time points to assess Ctrough of BMS-626529 following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Days 5, 6, 7, 8 and Day 8 evening dose (PM).
Time frame: Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours; Days 5,6,7: pre-evening dose
Area Under the Concentration-time Curve in One Dosing Interval (AUC [Tau]) of BMS-626529 Following Q12H Dosing
Blood samples were collected at indicated time points to assess AUC (tau) of BMS-626529 following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 morning dose (AM) and Day 8 evening dose (PM).
Time frame: Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours
AUC (Tau) of BMS-626529 Following QHS Dosing
Blood samples were collected at indicated time points to assess AUC (tau) of BMS-626529 following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1 and Day 8 evening dose (PM).
Time frame: Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours
Area Under the Concentration-time Curve Over a 24-hour Period (AUC [0-24]) of BMS-626529 Following Q12H Dosing
Blood samples were collected at indicated time points to assess AUC (0-24) of BMS-626529 following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8.
Time frame: Day 8: pre-morning dose, 1,2,3,4,5,6,8,12, 13,14,15,16,17,18,20 hours
AUC (0-24) of BMS-626529 Following QHS Dosing
Blood samples were collected at indicated time points to assess AUC (0-24) of BMS-626529 following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8.
Time frame: Day 8: pre-evening dose, 1,2,3,4,5,6,8 hours
Accumulation Index (AI) of BMS-626529 Following Q12H Dosing
Blood samples were collected at indicated time points to assess Accumulation Index of BMS-626529 following Q12H dosing. AI was calculated as ratio of AUC(tau) at steady-state to AUC(tau) after the first dose. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8 morning dose (AM).
Time frame: Day 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours
Accumulation Index of BMS-626529 Following QHS Dosing
Blood samples were collected at indicated time points to assess Accumulation Index of BMS-626529 following QHS dosing. AI was calculated as ratio of AUC(tau) at steady-state to AUC(tau) after the first dose. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8 evening dose (PM).
Time frame: Day 8: pre-evening dose, 1,2,3,4,5,6,8 hours
Inhibitory Quotient (IQ) of BMS-626529 by Css,Avg and by Lowest Concentration of a Drug During Dosing Interval (Cmin) Following Q12H Dosing
Blood samples were collected at indicated time points to assess IQ of BMS-626529. Inhibitory quotient was calculated as the ratio of BMS-626529 in vivo exposure to in vitro measured protein binding adjusted EC90 (PBA-EC90). The following in vivo exposure measures were used in evaluating IQ: Cmin and Css,avg. Geometric mean and geometric coefficient of variation are presented.
Time frame: Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours; Day 9: pre-dose, 4,12 hours; Day 10: pre-dose, 12 hours; Day 11: pre-dose; Days 5,6,7: pre-morning dose
Inhibitory Quotient (IQ) of BMS-626529 by Css,Avg and by Lowest Concentration of a Drug During Dosing Interval (Cmin) Following QHS Dosing
Blood samples were collected at indicated time points to assess IQ of BMS-626529. Inhibitory quotient was calculated as the ratio of BMS-626529 in vivo exposure to in vitro measured protein binding adjusted EC90 (PBA-EC90). The following in vivo exposure measures were used in evaluating IQ: Cmin and Css,avg. Geometric mean and geometric coefficient of variation are presented.
Time frame: Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours; Day 2: pre-evening dose, 12,16 hours; Day 9: pre-dose, 12,16 hours; Day 10: pre-dose, 12 hours; Day 11: pre-dose; Days 5,6,7: pre-evening dose
Inhibitory Quotient of BMS-626529 by Ctrough Following Q12H Dosing
Blood samples were collected at indicated time points to assess IQ of BMS-626529. Inhibitory quotient was calculated as the ratio of BMS-626529 in vivo exposure to in vitro measured protein binding adjusted EC90 (PBA-EC90). The following in vivo exposure measure was used in evaluating IQ: Ctrough. Geometric mean and geometric coefficient of variation are presented.
Time frame: Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours; Day 9: pre-dose, 4,12 hours; Day 10: pre-dose, 12 hours; Day 11: pre-dose; Days 5,6,7: pre-morning dose
Inhibitory Quotient of BMS-626529 by Ctrough Following QHS Dosing
Blood samples were collected at indicated time points to assess IQ of BMS-626529. Inhibitory quotient was calculated as the ratio of BMS-626529 in vivo exposure to in vitro measured protein binding adjusted EC90 (PBA-EC90). The following in vivo exposure measure was used in evaluating IQ: Ctrough. Geometric mean and geometric coefficient of variation are presented.
Time frame: Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours; Days 2: pre-evening dose, 12,16 hours; Day 9: pre-dose, 12,16 hours; Day 10: pre-dose, 12 hours; Day 11: pre-dose; Days 5,6,7: pre-evening dose
Cmax of Ritonavir Following Q12H Dosing
Blood samples were collected at indicated time points to assess Cmax of ritonavir following Q12H dosing. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 morning dose (AM), Day 8 evening dose (PM) and Day 8 morning + evening dose (AM+PM). Pharmacokinetic parameter values were derived by non-compartmental methods. PK Population was used which comprised of all participants who receive ritonavir and provided pharmacokinetic samples.
Time frame: Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours
Cmax of Ritonavir Following QHS Dosing
Blood samples were collected at indicated time points to assess Cmax of ritonavir following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 evening dose (PM) and Day 8 morning (AM) + evening dose (PM).
Time frame: Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours
Ctrough of Ritonavir Following Q12H Dosing
Blood samples were collected at indicated time points to access Ctrough of ritonavir following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Days 5, 6, 7, 8, Day 8 morning dose (AM) and Day 8 evening dose (PM).
Time frame: Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours; Days 5,6,7: pre-morning dose
Ctrough of Ritonavir Following QHS Dosing
Blood samples were collected at indicated time points to assess Ctrough of ritonavir following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Days 5, 6, 7, 8 and Day 8 evening dose (PM).
Time frame: Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours; Days 5,6,7: pre-evening dose
AUC (Tau) of Ritonavir Following Q12H Dosing
Blood samples were collected at indicated time points to assess AUC (tau) of ritonavir following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 morning dose (AM) and Day 8 evening dose (PM).
Time frame: Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours
AUC (Tau) of Ritonavir Following QHS Dosing
Blood samples were collected at indicated time points to assess AUC (tau) of ritonavir following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1 and Day 8 evening dose (PM).
Time frame: Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours
AUC (0-24) of Ritonavir Following Q12H Dosing
Blood samples were collected at indicated time points to assess AUC (0-24) of ritonavir following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8.
Time frame: Day 8: pre-morning dose, 1,2,3,4,5,6,8,12, 13,14,15,16,17,18,20 hours
AUC (0-24) of Ritonavir Following QHS Dosing
Blood samples were collected at indicated time points to assess AUC (0-24) of ritonavir following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8.
Time frame: Day 8: pre-evening dose, 1,2,3,4,5,6,8 hours
Accumulation Index of Ritonavir Following Q12H Dosing
Blood samples were collected at indicated time points to assess Accumulation Index of ritonavir following Q12H dosing. AI was calculated as ratio of AUC(tau) at steady-state to AUC(tau) after the first dose. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8 morning dose (AM).
Time frame: Day 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours
Accumulation Index of Ritonavir Following QHS Dosing
Blood samples were collected at indicated time points to assess Accumulation Index of ritonavir following QHS dosing. AI was calculated as ratio of AUC(tau) at steady-state to AUC(tau) after the first dose. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8 evening dose (PM).
Time frame: Day 8: pre-evening dose, 1,2,3,4,5,6,8 hours
This was a randomized, open label, multiple-dose study to evaluate the pharmacodynamics, safety and pharmacokinetics of BMS-663068 in human immunodeficiency virus 1 (HIV-1) infected participants. The study was conducted at single center in Germany.
| Milestone | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg QHS + RTV 100 mg QHS | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H |
|---|---|---|---|---|---|
| Started | 10 | 10 | 10 | 10 | 10 |
| Completed | 9 | 9 | 10 | 10 | 10 |
| Not completed | 1 | 1 | 0 | 0 | 0 |
| Withdrew: No longer met study criteria | 1 | 1 | 0 | 0 | 0 |
The primary assessment of the antiviral activity of BMS-663068 was assessed on the log10 change from Baseline in HIV RNA to Day 9. Baseline was the last non-missing observation before first dose (Day 1 pre-dose) and change from Baseline was calculated by subtracting Baseline value from post-Baseline visit value. An analysis of covariance (ANCOVA) model correcting for Baseline HIV viral load and treatment group was used to test the differences in mean log10 decrease in HIV RNA at Day 9 between 2 regimen groups by antiretroviral treatment history (ARV \[antiretroviral\] naive, ARV experienced, and combined \[ARV naive + ARV experienced\]). For the combined group (ARV naive +ARV experienced) an additional ANCOVA was used correcting also for treatment history as an additional covariate. Only Clade B participants were included in the population.
| Log10 copies per milliliter (c/mL) | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg QHS + RTV 100 mg QHS | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H |
|---|---|---|---|---|---|
| Mean Logarithm With Base 10 (Log10) Change From Baseline in Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) at Day 9 | -1.3445 ± 0.07925 | -1.2532 ± 0.10610 | -1.2381 ± 0.10455 | -1.1888 ± 0.12938 | -0.8760 ± 0.22621 |
Blood samples were collected for evaluation of CD4+ and CD8+ cells at Baseline (Day 1, pre-dose), Day 8, Day 15 (Follow up) and Day 50 (study discharge). Baseline was the last non-missing observation before first dose (Day 1 pre-dose) and change from Baseline was calculated by subtracting Baseline value from post-Baseline visit value.
| Cells per microliter (cells/μL) | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg QHS + RTV 100 mg QHS | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H |
|---|---|---|---|---|---|
| CD4+, Day 8, n=9, 9, 10, 10, 10 | 114.2 ± 74.55 | 93.4 ± 25.12 | 109.8 ± 32.37 | 38.5 ± 41.61 | 32.0 ± 36.23 |
| CD4+, Day 15, n=9, 9, 10, 10, 10 | 58.4 ± 92.14 | -6.1 ± 28.15 | 117.6 ± 27.67 | 44.6 ± 69.94 | 10.4 ± 23.38 |
| CD4+, Day 50, n=9, 9, 10, 10, 9 | 22.0 ± 91.55 | -50.3 ± 18.06 | 71.1 ± 28.55 | -48.4 ± 61.21 | -19.2 ± 17.05 |
| CD8+, Day 8, n=9, 9, 10, 10, 10 | 384.2 ± 164.35 | 189.0 ± 134.27 | 218.4 ± 125.65 | 114.9 ± 131.64 | 94.6 ± 152.73 |
| CD8+, Day 15, n=9, 9, 10, 10, 10 | 64.8 ± 230.86 | -153.2 ± 137.18 | 85.6 ± 112.65 | -99.6 ± 159.83 | -4.4 ± 126.77 |
| CD8+, Day 50, n=9, 9, 10, 10, 9 | -37.6 ± 161.11 | -292.4 ± 121.73 | 139.7 ± 95.00 | 6.0 ± 170.29 | -48.2 ± 140.55 |
Blood samples were collected for evaluation of percent CD4+ and percent CD8+ cells at Baseline (Day 1, pre-dose), Day 8, Day 15 (Follow up) and Day 50 (study discharge). Baseline was the last non-missing observation before first dose (Day 1 pre-dose) and change from Baseline was calculated by subtracting Baseline visit value from post-Baseline visit value.
| Percent cells per microliter | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg QHS + RTV 100 mg QHS | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H |
|---|---|---|---|---|---|
| Percent CD4+, Day 8, n=9, 9, 10, 10, 10 | -1.0 ± 1.12 | 1.2 ± 0.97 | 0.6 ± 0.78 | 0.1 ± 0.72 | 1.4 ± 1.11 |
| Percent CD4+, Day 15, n=9, 9, 10, 10, 10 | 1.6 ± 1.00 | 1.2 ± 0.64 | 1.4 ± 1.33 | 2.4 ± 1.11 | 0.9 ± 1.51 |
| Percent CD4+, Day 50, n=9, 9, 10, 10, 9 | 1.4 ± 0.84 | 1.1 ± 1.15 | 0.3 ± 0.90 | -1.7 ± 0.97 | 0.6 ± 1.45 |
| Percent CD8+, Day 8, n=9, 9, 10, 10, 10 | 1.0 ± 0.76 | -0.4 ± 1.02 | 0.1 ± 1.06 | -0.3 ± 1.11 | -0.2 ± 1.20 |
| Percent CD8+, Day 15, n=9, 9, 10, 10, 10 | -3.4 ± 0.73 | -2.8 ± 1.00 | -2.9 ± 1.49 | -4.0 ± 1.73 | -2.9 ± 1.16 |
| Percent CD8+, Day 50, n=9, 9, 10, 10, 9 | -2.2 ± 1.01 | -0.7 ± 1.22 | -0.9 ± 1.19 | 1.6 ± 1.52 | -2.4 ± 1.57 |
An AE is any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Any untoward medical occurrence resulting in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent serious outcomes were categorized as SAE. Treatment emergent adverse events (occurred after start of treatment) have been presented.Safety Population comprised of all randomized participants who used the trial medication at least once.
| Participants | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg QHS + RTV 100 mg QHS | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H |
|---|---|---|---|---|---|
| Non-SAE | 8 | 5 | 9 | 8 | 9 |
| SAE | 0 | 0 | 0 | 0 | 0 |
A complete physical examination included, at a minimum, assessment of the Cardiovascular, Respiratory, Gastrointestinal and Neurological systems. A brief physical examination included, at a minimum assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). Any abnormality found by investigator during physical examination were recorded. Number of participants with any abnormality in physical examination during study have been reported.
| Participants | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg QHS + RTV 100 mg QHS | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H |
|---|---|---|---|---|---|
| Number of Participants With Any Abnormality in Physical Examination | 1 | 0 | 2 | 1 | 1 |
Vital signs including DBP and SBP were recorded. Normal ranges were as following: For DBP, lower limit: value \<55 millimeter of mercury (mmHg) and change \<-20 mmHg; upper limit: value \>90 mmHg and change \>20 mmHg). For SBP, lower limit: value \<90 mmHg and change \<-10 mmHg; upper limit: value \>140 mmHg and change \>10 mmHg. Number of participants with worst-case abnormalities are presented. Worst-case abnormality was defined as: (1) Below Normal: at least one post-Baseline assessment was below normal range, and no post-Baseline assessment was above normal range. (2) Above Normal: at least one post-Baseline assessment was above normal range, and no post-Baseline assessment was below normal range. (3) Within Normal: all post-Baseline assessments were within normal range. It was to be considered as 'Missing' when there were no post-Baseline assessments.
| Participants | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg QHS + RTV 100 mg QHS | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H |
|---|---|---|---|---|---|
| SBP, Above Normal | 0 | 3 | 1 | 0 | 1 |
| SBP, Below Normal | 0 | 0 | 0 | 0 | 0 |
| SBP, Within Normal | 10 | 7 | 9 | 10 | 9 |
| DBP, Above Normal | 0 | 0 | 0 | 0 | 0 |
| DBP, Below Normal | 0 | 0 | 0 | 0 | 0 |
| DBP, Within Normal | 10 | 10 | 10 | 10 | 10 |
Vital signs (body temperature, RR, and HR) were recorded. Normal range were: For HR, lower limit: 55 beats per minute (bpm) and change \<-15 bpm; upper limit: \>100 bpm and change \>30 bpm). For temperature, lower limit: 36.0 Celsius; upper limit: \>37.5 Celsius or change \>1.7 Celsius). For RR, lower limit: 8 breaths per minute; upper limit: \>16 breaths per minute or change \>10 breaths per minute. Number of participants with worst-case abnormalities are presented. Worst-case abnormality was defined as: (1) Below Normal: at least one post-Baseline assessment was below normal range, and no post-Baseline assessment was above normal range. (2) Above Normal: at least one post-Baseline assessment was above normal range, and no post-Baseline assessment was below normal range. (3) Within Normal: all post-Baseline assessments were within normal range. It was to be considered as 'Missing' when there were no post-Baseline assessments.
| Participants | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg QHS + RTV 100 mg QHS | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H |
|---|---|---|---|---|---|
| HR, Above Normal | 0 | 0 | 0 | 0 | 0 |
| HR, Below Normal | 1 | 2 | 1 | 0 | 1 |
| HR, Within Normal | 9 | 8 | 9 | 10 | 9 |
| RR, Above Normal | 4 | 3 | 3 | 3 | 8 |
| RR, Below Normal | 0 | 0 | 0 | 0 | 0 |
| RR, Within Normal | 6 | 7 | 7 | 7 | 2 |
| Temperature, Above Normal | 0 | 0 | 0 | 0 | 0 |
| Temperature, Below Normal | 1 | 2 | 0 | 1 | 0 |
| Temperature, Within Normal | 9 | 8 | 10 | 9 | 10 |
A 12-lead ECG was recorded during the study using an ECG machine that automatically measures ECG parameters. Normal range for ECG parameters were: PR interval (upper: 200 milliseconds \[ms\]); QRS (lower: 50 ms; upper: 120 ms); Corrected QT interval by Bazett formula (QTcB) (change from Baseline - increases by \> 30 ms); Corrected QT interval by Fredericia formula (QTcF) (change from Baseline - increases by \> 30 ms). Number of participants with worst-case abnormalities are presented which was defined as: (1) Below Normal: at least one post-Baseline assessment was below normal range, and no post-Baseline assessment was above normal range. (2) Above Normal: at least one post-Baseline assessment was above normal range, and no post-Baseline assessment was below normal range. Within Normal: all post-Baseline assessments were within normal range. It was to be considered as 'Missing' when there were no post-Baseline assessments.
| Participants | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg QHS + RTV 100 mg QHS | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H |
|---|---|---|---|---|---|
| PR interval, Above Normal | 0 | 1 | 0 | 0 | 1 |
| PR interval, Below Normal | 0 | 0 | 0 | 0 | 0 |
| PR interval, Within Normal | 10 | 9 | 10 | 10 | 9 |
| QTcB, Above Normal | 0 | 1 | 2 | 0 | 1 |
| QTcB, Below Normal | 0 | 0 | 0 | 0 | 0 |
| QTcB, Within Normal | 10 | 9 | 8 | 10 | 9 |
| QTcF, Above Normal | 1 | 0 | 1 | 0 | 2 |
| QTcF, Below Normal | 0 | 0 | 0 | 0 | 0 |
| QTcF, Within Normal | 9 | 10 | 9 | 10 | 8 |
Laboratory parameters included hematology, clinical chemistry and urine parameters. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Any abnormal laboratory test results which were considered clinically significant by the investigator were recorded on the case report form. Number of participants with any clinically significant abnormalities in laboratory parameters have been presented.
| Participants | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg QHS + RTV 100 mg QHS | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected at indicated time points to assess Cmax of BMS-626529 following Q12H dosing. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 morning dose (Anti Meridiem \[AM\]), Day 8 evening dose (Post Meridiem \[PM\]) and Day 8 morning + evening dose (AM+PM). Pharmacokinetic parameter values were derived by non-compartmental methods. Pharmacokinetic (PK) Population was used which comprised of all participants who receive BMS-663068 and provided pharmacokinetic samples.
| Micrograms per milliliter (μg/mL) | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H |
|---|---|---|---|---|
| Day 1, n=10,10,10,10 | 1.74 ± 59.9 | 3.52 ± 26.6 | 4.05 ± 35.8 | 2.55 ± 27.4 |
| Day 8, AM, n=9,10,10,10 | 2.22 ± 67.1 | 5.55 ± 37.5 | 5.10 ± 57.4 | 3.18 ± 22.0 |
| Day 8, PM, n=9,10,10,10 | 2.25 ± 46.4 | 4.60 ± 29.2 | 4.77 ± 36.2 | 3.61 ± 27.5 |
| Day 8, AM+PM, n=9,10,10,10 | 2.24 ± 43.3 | 5.05 ± 31.7 | 4.93 ± 40.1 | 3.39 ± 15.9 |
Blood samples were collected at indicated time points to assess Cmax of BMS-626529 following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 evening dose (PM) and Day 8 morning (AM) + evening dose (PM).
| μg/mL | BMS-663068 1200 mg QHS + RTV 100 mg QHS |
|---|---|
| Day 1, n=10 | 3.85 ± 32.0 |
| Day 8, PM, n=9 | 3.47 ± 31.7 |
| Day 8, AM+PM, n=9 | 3.47 ± 31.7 |
Blood samples were collected at indicated time points to access Ctrough of BMS-626529 following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Days 5, 6, 7, 8, Day 8 morning dose (AM) and Day 8 evening dose (PM).
| Micrograms per milliliter (μg/mL) | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H |
|---|---|---|---|---|
| Day 1, n=10,10,10,10 | 0.349 ± 156 | 0.499 ± 83.4 | 0.640 ± 114 | 0.244 ± 78.3 |
| Day 5, n=9,10,10,10 | 0.473 ± 119 | 1.04 ± 72.2 | 0.760 ± 67.1 | 0.518 ± 48.2 |
| Day 6, n=9,10,10,10 | 0.436 ± 89.5 | 0.839 ± 49.1 | 0.737 ± 73.2 | 0.451 ± 49.2 |
| Day 7, n=9,10,10,10 | 0.495 ± 96.5 | 1.08 ± 72.9 | 0.998 ± 91.8 | 0.542 ± 73.5 |
| Day 8, n=9,10,10,10 | 0.460 ± 89.2 | 0.743 ± 47.1 | 0.720 ± 83.5 | 0.628 ± 76.9 |
| Day 8, AM, n=9,10,10,10 | 0.422 ± 69.1 | 0.951 ± 88.2 | 0.579 ± 71.5 | 0.469 ± 122 |
| Day 8, PM, n=9,10,10,10 | 0.358 ± 102 | 0.653 ± 109 | 0.553 ± 68.1 | 0.487 ± 47.5 |
Blood samples were collected at indicated time points to assess Ctrough of BMS-626529 following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Days 5, 6, 7, 8 and Day 8 evening dose (PM).
| μg/mL | BMS-663068 1200 mg QHS + RTV 100 mg QHS |
|---|---|
| Day 1, n=10 | 0.699 ± 93.4 |
| Day 5, n=9 | 0.0705 ± 114 |
| Day 6, n=9 | 0.0743 ± 97.7 |
| Day 7, n=9 | 0.0719 ± 166 |
| Day 8, n=9 | 0.0546 ± 146 |
| Day 8, PM, n=9 | 0.0544 ± 156 |
Blood samples were collected at indicated time points to assess AUC (tau) of BMS-626529 following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 morning dose (AM) and Day 8 evening dose (PM).
| Hour*micrograms per milliliter | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H |
|---|---|---|---|---|
| Day 1, n=10,10,10,10 | 9.16 ± 68.7 | 18.3 ± 28.8 | 20.6 ± 45.0 | 13.8 ± 28.3 |
| Day 8, AM, n=9,10,10,10 | 13.1 ± 62.7 | 29.9 ± 37.0 | 27.6 ± 48.4 | 19.5 ± 20.5 |
| Day 8, PM, n=9,10,10,10 | 13.1 ± 63.8 | 30.6 ± 26.3 | 27.0 ± 45.2 | 22.5 ± 34.0 |
Blood samples were collected at indicated time points to assess AUC (tau) of BMS-626529 following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1 and Day 8 evening dose (PM).
| Hour*micrograms per milliliter | BMS-663068 1200 mg QHS + RTV 100 mg QHS |
|---|---|
| Day 1, n=10 | 25.5 ± 38.0 |
| Day 8 PM, n=9 | 23.0 ± 48.2 |
Blood samples were collected at indicated time points to assess AUC (0-24) of BMS-626529 following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8.
| Hour*micrograms per milliliter | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H |
|---|---|---|---|---|
| Area Under the Concentration-time Curve Over a 24-hour Period (AUC [0-24]) of BMS-626529 Following Q12H Dosing | 26.8 ± 56.1 | 60.6 ± 30.6 | 55.1 ± 44.3 | 42.6 ± 21.5 |
Blood samples were collected at indicated time points to assess AUC (0-24) of BMS-626529 following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8.
| Hour*micrograms per milliliter | BMS-663068 1200 mg QHS + RTV 100 mg QHS |
|---|---|
| AUC (0-24) of BMS-626529 Following QHS Dosing | 23.0 ± 48.2 |
Blood samples were collected at indicated time points to assess Accumulation Index of BMS-626529 following Q12H dosing. AI was calculated as ratio of AUC(tau) at steady-state to AUC(tau) after the first dose. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8 morning dose (AM).
| Ratio of AUC | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H |
|---|---|---|---|---|
| Accumulation Index (AI) of BMS-626529 Following Q12H Dosing | 1.53 ± 49.4 | 1.63 ± 26.7 | 1.34 ± 25.4 | 1.42 ± 37.0 |
Blood samples were collected at indicated time points to assess Accumulation Index of BMS-626529 following QHS dosing. AI was calculated as ratio of AUC(tau) at steady-state to AUC(tau) after the first dose. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8 evening dose (PM).
| Ratio of AUC | BMS-663068 1200 mg QHS + RTV 100 mg QHS |
|---|---|
| Accumulation Index of BMS-626529 Following QHS Dosing | 0.912 ± 27.1 |
Blood samples were collected at indicated time points to assess IQ of BMS-626529. Inhibitory quotient was calculated as the ratio of BMS-626529 in vivo exposure to in vitro measured protein binding adjusted EC90 (PBA-EC90). The following in vivo exposure measures were used in evaluating IQ: Cmin and Css,avg. Geometric mean and geometric coefficient of variation are presented.
| Ratio | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H |
|---|---|---|---|---|
| IQ Cmin | 11.0 ± 3510 | 97.5 ± 382 | 67.2 ± 543 | 4.54 ± 21600 |
| IQ Css,avg | 29.7 ± 4040 | 327 ± 454 | 252 ± 789 | 15.4 ± 14900 |
Blood samples were collected at indicated time points to assess IQ of BMS-626529. Inhibitory quotient was calculated as the ratio of BMS-626529 in vivo exposure to in vitro measured protein binding adjusted EC90 (PBA-EC90). The following in vivo exposure measures were used in evaluating IQ: Cmin and Css,avg. Geometric mean and geometric coefficient of variation are presented.
| Ratio | BMS-663068 1200 mg QHS + RTV 100 mg QHS |
|---|---|
| IQ Cmin | 3.86 ± 1070 |
| IQ Css,avg | 67.8 ± 902 |
Blood samples were collected at indicated time points to assess IQ of BMS-626529. Inhibitory quotient was calculated as the ratio of BMS-626529 in vivo exposure to in vitro measured protein binding adjusted EC90 (PBA-EC90). The following in vivo exposure measure was used in evaluating IQ: Ctrough. Geometric mean and geometric coefficient of variation are presented.
| Ratio | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H |
|---|---|---|---|---|
| Inhibitory Quotient of BMS-626529 by Ctrough Following Q12H Dosing | 12.2 ± 2750 | 120 ± 568 | 87.3 ± 763 | 4.61 ± 19000 |
Blood samples were collected at indicated time points to assess IQ of BMS-626529. Inhibitory quotient was calculated as the ratio of BMS-626529 in vivo exposure to in vitro measured protein binding adjusted EC90 (PBA-EC90). The following in vivo exposure measure was used in evaluating IQ: Ctrough. Geometric mean and geometric coefficient of variation are presented.
| Ratio | BMS-663068 1200 mg QHS + RTV 100 mg QHS |
|---|---|
| Inhibitory Quotient of BMS-626529 by Ctrough Following QHS Dosing | 4.77 ± 1010 |
Blood samples were collected at indicated time points to assess Cmax of ritonavir following Q12H dosing. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 morning dose (AM), Day 8 evening dose (PM) and Day 8 morning + evening dose (AM+PM). Pharmacokinetic parameter values were derived by non-compartmental methods. PK Population was used which comprised of all participants who receive ritonavir and provided pharmacokinetic samples.
| Micrograms per milliliter (μg/mL) | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM |
|---|---|---|---|
| Day 1, n=10,10,10 | 0.330 ± 91.3 | 0.314 ± 111 | 0.294 ± 59.6 |
| Day 8, AM, n=9,10,10 | 1.31 ± 101 | 1.30 ± 58.3 | 0.841 ± 44.9 |
| Day 8, PM, n=9,10,0 | 1.24 ± 73.4 | 1.48 ± 47.7 | — |
| Day 8, AM+PM, n=9,10,10 | 1.27 ± 80.0 | 1.39 ± 50.7 | 0.841 ± 44.9 |
Blood samples were collected at indicated time points to assess Cmax of ritonavir following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 evening dose (PM) and Day 8 morning (AM) + evening dose (PM).
| μg/mL | BMS-663068 1200 mg QHS + RTV 100 mg QHS |
|---|---|
| Day 1, n=10 | 0.257 ± 53.8 |
| Day 8, PM, n=9 | 0.628 ± 56.4 |
| Day 8, AM+PM, n=9 | 0.628 ± 56.4 |
Blood samples were collected at indicated time points to access Ctrough of ritonavir following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Days 5, 6, 7, 8, Day 8 morning dose (AM) and Day 8 evening dose (PM).
| Micrograms per milliliter (μg/mL) | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM |
|---|---|---|---|
| Day 1, n=10,10,0 | 0.117 ± 90.1 | 0.131 ± 98.2 | — |
| Day 5, n=9,10,10 | 0.502 ± 84.3 | 0.554 ± 73.9 | 0.0831 ± 77.8 |
| Day 6, n=9,10,10 | 0.526 ± 87.9 | 0.594 ± 77.0 | 0.0820 ± 77.9 |
| Day 7, n=9,10,10 | 0.477 ± 93.5 | 0.587 ± 76.3 | 0.0860 ± 79.9 |
| Day 8, n=9,10,10 | 0.470 ± 90.6 | 0.503 ± 73.2 | 0.0891 ± 81.7 |
| Day 8, AM, n=9,10,10 | 0.345 ± 105 | 0.393 ± 66.3 | 0.0912 ± 70.5 |
| Day 8, PM, n=9,10,0 | 0.453 ± 86.2 | 0.476 ± 77.9 | — |
Blood samples were collected at indicated time points to assess Ctrough of ritonavir following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Days 5, 6, 7, 8 and Day 8 evening dose (PM).
| μg/mL | BMS-663068 1200 mg QHS + RTV 100 mg QHS |
|---|---|
| Day 1, n=10 | 0.157 ± 87.0 |
| Day 5, n=9 | 0.107 ± 69.4 |
| Day 6, n=9 | 0.0845 ± 67.7 |
| Day 7, n=9 | 0.0844 ± 65.0 |
| Day 8, n=9 | 0.0808 ± 73.2 |
| Day 8, PM, n=9 | 0.0830 ± 71.7 |
Blood samples were collected at indicated time points to assess AUC (tau) of ritonavir following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 morning dose (AM) and Day 8 evening dose (PM).
| Hour*micrograms per milliliter | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM |
|---|---|---|---|
| Day 1, n=10,10,0 | 2.37 ± 99.5 | 2.05 ± 104 | — |
| Day 8, AM, n=9,10,10 | 9.43 ± 89.1 | 9.05 ± 62.8 | 6.76 ± 49.3 |
| Day 8, PM, n=9,10,0 | 9.23 ± 77.1 | 10.4 ± 52.4 | — |
Blood samples were collected at indicated time points to assess AUC (tau) of ritonavir following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1 and Day 8 evening dose (PM).
| Hour*micrograms per milliliter | BMS-663068 1200 mg QHS + RTV 100 mg QHS |
|---|---|
| Day 1, n=10 | 2.91 ± 80.4 |
| Day 8 PM, n=9 | 6.13 ± 94.3 |
Blood samples were collected at indicated time points to assess AUC (0-24) of ritonavir following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8.
| Hour*micrograms per milliliter | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM |
|---|---|---|---|
| AUC (0-24) of Ritonavir Following Q12H Dosing | 18.9 ± 80.0 | 19.5 ± 56.6 | 6.76 ± 49.3 |
Blood samples were collected at indicated time points to assess AUC (0-24) of ritonavir following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8.
| Hour*micrograms per milliliter | BMS-663068 1200 mg QHS + RTV 100 mg QHS |
|---|---|
| AUC (0-24) of Ritonavir Following QHS Dosing | 6.13 ± 94.3 |
Blood samples were collected at indicated time points to assess Accumulation Index of ritonavir following Q12H dosing. AI was calculated as ratio of AUC(tau) at steady-state to AUC(tau) after the first dose. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8 morning dose (AM).
| Ratio of AUC | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM |
|---|---|---|---|
| Accumulation Index of Ritonavir Following Q12H Dosing | 3.58 ± 64.0 | 4.41 ± 41.7 | 3.62 ± 39.8 |
Blood samples were collected at indicated time points to assess Accumulation Index of ritonavir following QHS dosing. AI was calculated as ratio of AUC(tau) at steady-state to AUC(tau) after the first dose. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8 evening dose (PM).
| Ratio of AUC | BMS-663068 1200 mg QHS + RTV 100 mg QHS |
|---|---|
| Accumulation Index of Ritonavir Following QHS Dosing | 2.19 ± 16.2 |
Collected over Serious adverse events (SAEs) and Non-serious adverse events (Non-SAEs) were collected from the start of the study treatment up to 50 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BMS-663068 600 mg Q12H + RTV 100 mg Q12H | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| BMS-663068 1200 mg QHS + RTV 100 mg QHS | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| BMS-663068 1200 mg Q12H + RTV 100 mg QAM | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| BMS-663068 1200 mg Q12H | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| Event | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg QHS + RTV 100 mg QHS | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H |
|---|---|---|---|---|---|
| HEADACHENervous system disorders | 4/10 | 3/10 | 4/10 | 3/10 | 4/10 |
| NASOPHARYNGITISInfections and infestations | 1/10 | 0/10 | 3/10 | 2/10 | 0/10 |
| MICTURITION URGENCYRenal and urinary disorders | 1/10 | 1/10 | 1/10 | 1/10 | 3/10 |
| DIARRHOEAGastrointestinal disorders | 1/10 | 0/10 | 0/10 | 1/10 | 2/10 |
| TOOTHACHEGastrointestinal disorders | 0/10 | 0/10 | 2/10 | 0/10 | 0/10 |
| DISORIENTATIONPsychiatric disorders | 1/10 | 0/10 | 1/10 | 0/10 | 2/10 |
| ERYTHEMASkin and subcutaneous tissue disorders | 1/10 | 0/10 | 0/10 | 2/10 | 1/10 |
| RASHSkin and subcutaneous tissue disorders | 2/10 | 1/10 | 2/10 | 1/10 | 2/10 |
| PALPITATIONSCardiac disorders | 1/10 | 0/10 | 0/10 | 0/10 | 0/10 |
| EYE PRURITUSEye disorders | 0/10 | 0/10 | 1/10 | 0/10 | 0/10 |
| Age, Continuous(Years) | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg QHS + RTV 100 mg QHS | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H | Total |
|---|---|---|---|---|---|---|
| Mean | 41.3 ± 8.29 | 40.7 ± 13.70 | 40.7 ± 6.53 | 38.4 ± 7.83 | 42.7 ± 8.42 | 40.8 ± 9.01 |
| Sex: Female, Male(Participants) | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg QHS + RTV 100 mg QHS | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 1 | 1 | 0 | 0 | 3 |
| Male | 9 | 9 | 9 | 10 | 10 | 47 |
| Race/Ethnicity, Customized(Participants) | BMS-663068 600 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg QHS + RTV 100 mg QHS | BMS-663068 1200 mg Q12H + RTV 100 mg Q12H | BMS-663068 1200 mg Q12H + RTV 100 mg QAM | BMS-663068 1200 mg Q12H | Total |
|---|---|---|---|---|---|---|
| Race — White | 10 | 10 | 10 | 10 | 10 | 50 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2009 to primary completion in Jun 2010, 7 months.
Results were first posted in Jan 2020, 9 years 6 months after primary completion.
Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 7 months is below that.
Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fostemsavir